Benjamin Forred, Translational Research Project Manager at Sanford Health in Sioux Falls, South Dakota, discusses his organization which is one of the largest health systems in the United States, including research into rare diseases.
Dan O’Connor, President, Director and Chief Executive Officer of OncoSec discusses the KEYNOTE-695 Study of TAVO + Keytruda in Refractory Metastatic Melanoma.
Ron Philip, Chief Commercial Officer of Spark Therapeutics, discusses gene testing for inherited eye diseases, including his company’s initative EyeWant2Know.com.
Dan O’Connor, President, Director and Chief Executive Officer of OncoSec discusses his company and it’s focus on developing cytokine-based intratumoral immunotherapies to stimulate the body’s immune system to target and attack cancer.
Pushkal Garg, MD, Chief Medical Officer at Alnylam provides an overview of his company and its focus on RNA interference (RNAi).
Armando Anido, Chief Executive Officer at Zynerba Pharmaceuticals discusses his company’s lead product candidate ZYN002, a CBD gel currently being evaluated for Fragile X syndrome.